跳到页面内容
pepts.wiki

我们不是医生,此处的内容均不构成医疗建议。请务必先咨询医疗专业人员。 我们为何这样表述

机器翻译,以英文为准。 阅读英文原文

动物和细胞研究Stub

PNC-27

p53衍生肽

一种含有p53蛋白MDM2结合区一部分的肽,曾在实验室中针对癌细胞进行研究。

复溶计算器

概览

动物和细胞研究

已发表的证据来自动物和细胞。已发表的对照人体试验极少或没有。

本页内容尚不完整

The wiki has this compound's identity from the My-Pepts library, its standing, and what PubMed holds for it. The article, with its studies read and cited, is not written yet. Until it is, the counts below say how much research exists, not what it found.

证据有多强

它攀登到了哪一级

每种药物都要攀登同一架阶梯。大多数化合物从未到达顶端,其所处位置决定了其主张能有多大的依据。

  1. 已获许可的药物

    监管机构已审查这些试验,并批准其用于特定用途。

  2. Phase 3

    大型随机试验,通常有数千人,与安慰剂或标准治疗对照。

  3. Phase 2

    中等规模试验,在患有相应疾病的人群中测量剂量与效果的关系。

  4. Phase 1 and early human studies

    首次在人体中进行的研究:安全性以及身体如何处理该物质。

  5. 细胞与动物: PNC-27

    实验室及动物研究。动物实验的结果不等同于人体结果。

23
PubMed 上的论文
17
其中以人为对象的研究
0
随机试验
2
综述

文献数量只说明发表了多少,并不说明结果如何。在 PubMed 上统计的数量: 2026-11-16

处理与复溶

从粉末到测量好的样品

对任何冻干小瓶都是同样的四个步骤。仅指实验室操作,并非用于人体。

  1. 1. 阅读小瓶标签

    标签给出小瓶中肽的质量,单位为毫克。这个数字是所有计算的起点。

  2. 2. 加入稀释剂

    将量好的稀释剂沿玻璃壁缓慢加入。轻轻旋转;摇晃可能损伤肽。

  3. 3. 计算浓度

    浓度等于质量除以体积:10 毫克溶于 2 毫升即为每毫升 5 毫克。

  4. 4. 量取样品

    体积等于所需质量除以浓度。在 U-100 注射器上,1 毫升即 100 单位。

下方的计算器会完成运算并显示计算过程。

As powder

General practice for lyophilized peptides: keep the sealed vial frozen or refrigerated, dry and away from light, and follow the supplier's certificate of analysis.

In solution

Once in solution a peptide is kept refrigerated and used within the period the supplier states. A vial drawn from more than once needs a preserved diluent such as bacteriostatic water.

This is general practice for lyophilized peptides, not data on PNC-27 itself. The batch's certificate of analysis and the supplier's sheet are the facts to go by. More on storage

Reconstitution calculator

Opens on vial sizes common for research peptides. Change any number. How the arithmetic works

Draw to

10 units

0.1 mL on a U-100 syringe

Concentration
2.5 mg/mL
Each unit holds
25 mcg
Samples in the vial
20
Sample
250 mcg

5 mg in 2 mL is 2.5 mg/mL. 250 mcg of that is 0.1 mL, which reads as 10 units. This is arithmetic for a vial of PNC-27; no amount here is a recommendation.

PNC-27: PubMed 上的文献

What PubMed held for PNC-27 on November 16, 2026. A count says how much a compound has been studied, not what the studies found: how to read these numbers.

23
papers
17
in humans
0
clinical trials
0
randomized trials
2012: 0 papers122013: 0 papers2014: 1 papers142015: 1 papers2016: 1 papers162017: 1 papers2018: 1 papers182019: 1 papers2020: 3 papers202021: 1 papers2022: 2 papers222023: 2 papers2024: 2 papers242025: 1 papers2026: 0 papers so far26
Papers per year, 2012 to 2026. The most in one year: 3.

Most relevant on PubMed

Listed by PubMed's own relevance ranking, trials and reviews first. The wiki has not read these into the article unless they are also among its sources.

  1. Conjugated PNC-27 peptide/PEI-superparamagnetic iron oxide nanoparticles (SPIONs) as a double targeting agent for early cancer diagnosis: In vitro study

    StudyRahmani R, Darroudi M, Gharanfoli M, et al. Iranian journal of basic medical sciences, 2022. PMID 36311203

  2. HDM-2-Targeting Peptide PNC-27 Kills Cervical Cancer Cells but not Normal Cervical Cells

    StudyKrzesaj PK, Seydafkan S, Miller AI, et al. Annals of clinical and laboratory science, 2025. PMID 40750238

  3. PNC-27, a Chimeric p53-Penetratin Peptide Binds to HDM-2 in a p53 Peptide-like Structure, Induces Selective Membrane-Pore Formation and Leads to Cancer Cell Lysis

    StudySarafraz-Yazdi E, Mumin S, Cheung D, et al. Biomedicines, 2022. PMID 35625682

  4. Anti-Cancer Peptide PNC-27 Kills Cancer Cells by Unique Interactions with Plasma Membrane-Bound hdm-2 and with Mitochondrial Membranes Causing Mitochondrial Disruption

    StudyKrzesaj P, Adler V, Feinman RD, et al. Annals of clinical and laboratory science, 2024. PMID 38802154

  5. Poptosis or Peptide-Induced Transmembrane Pore Formation: A Novel Way to Kill Cancer Cells without Affecting Normal Cells

    ReviewPincus MR, Silberstein M, Zohar N, et al. Biomedicines, 2024. PMID 38927351

  6. Anti-cancer peptides from ras-p21 and p53 proteins

    ReviewPincus MR, Fenelus M, Sarafraz-Yazdi E, et al. Current pharmaceutical design, 2011. PMID 21728981

Search used: ("PNC-27"[tiab]). Run it on PubMed

研究链接

Also in Other